Survodutide 10mg
BI Dual GLP-1/Glucagon Agonist for NASH and Obesity Research
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim showing significant weight loss and liver fat reduction in Phase 2 trials for both obesity and NASH.
BI Dual GLP-1/Glucagon Agonist for NASH and Obesity Research
Survodutide combines GLP-1R-mediated appetite suppression with GCGR-driven hepatic fat oxidation and energy expenditure increase, showing particular promise for NASH treatment alongside obesity research.
As one of the most studied compounds in the metabolic & fat loss research space, Survodutide has attracted sustained scientific interest across NASH research, Next-generation obesity studies, Dual GLP-1/glucagon research. Peer-reviewed evidence indicates that phase 2 NASH data showing liver fat reduction, which has positioned Survodutide as a reference standard for researchers exploring nash research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Survodutide Documented Benefits: 2 Documented Mechanisms
NASH Treatment Potential
Phase 2 data shows significant liver fat reduction in NASH patients.
Significant Weight Loss
Dual mechanism produces substantial weight reduction in obesity trials.
How Survodutide Works: Molecular Mechanism & Pathway
Dual GLP-1R/GCGR agonist with complementary appetite suppression and energy expenditure pathways.
The 2 primary research pathways identified for Survodutide — NASH Treatment Potential, Significant Weight Loss — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that significant weight loss in obesity trials, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Survodutide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Survodutide is routinely studied alongside Tirzepatide and Retatrutide in metabolic & fat loss-focused compound panels. Researchers investigating nash research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that boehringer Ingelheim IND compound has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Survodutide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 2 NASH data showing liver fat reduction
- Significant weight loss in obesity trials
- Boehringer Ingelheim IND compound
Ideal For
- NASH research
- Next-generation obesity studies
- Dual GLP-1/glucagon research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Survodutide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 2 NASH data showing liver fat reduction
Significant weight loss in obesity trials
Boehringer Ingelheim IND compound
Third-Party Verified Every Batch
Each vial of Survodutide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
